SLC16A3 and breast cancer: Notably, scientists have identified MCT4, PD-L1, CD163, and FOXP3 as important markers for the prognosis of TNBC [28], which not only redefines markers for molecular subtypes of breast cancer but facilitates progress for dual-targeted therapy research in triple-negative breast cancer.